Publications

Kwon DH, Scheuner MT, McPhaul M, Hearst EL, Sumra S, Ursem C, Walker E, Wang S, Kaur G, Nesheiwat S, Huang FW, Aggarwal RR, Belkora J. Veterans' Decision Making for Prostate Cancer Germline Testing After Informed Consent With Their Oncologist: A Mixed-Methods Study. JCO oncology practice. 2025. PMID: 40554736

Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ, AIM-HIGH investigators. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. The Lancet. Respiratory medicine. 2025. PMID: 40578381

Tsai KK, Komanduri KV. Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma. American journal of clinical dermatology. 2025. PMID: 40549109

Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G, Hylton N, Perlmutter J, DeMichele A, Yee D, van 't Veer L, Rugo H, Symmans WF, Goetz MP, Esserman L, Boughey JC. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. Breast cancer research : BCR. 2025. PMID: 40551254

Farhan S, Kennedy VE, Espinoza-Gutarra MR, Lust H, Bobillo MSO, Lin AY, Olin RL, Lin RJ, Rentscher KE, Taylor MR, Mohanraj L, Wood WA, Murthy HS, Ahmed N, Dueck AC, Phelan R, Kelly DL, Yuen C, Munshi PN, Schoemans H, Hamilton BK, Lee C, Sung AD. Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT. Transplantation and cellular therapy. 2025. PMID: 40545000

Yazdani A, Yazdani A, Mendez-Giraldez R, Pillonetto G, Samiei E, Hadi R, Lenz HJ, Venook AP, Samiei A, Nixon AB, Lucci JA, Kopetz S, Bertagnolli MM, Innocenti F. Novel treatment-specific causal biomarkers for colorectal cancer by omics integration. NAR genomics and bioinformatics. 2025. PMID: 40585306

Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, Kwok M, Cicero KI, Hirayama AV, Basom R, Khouderchah C, Shadman M, Fong L, Cowan AJ, Gauthier J. Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica. 2025. PMID: 40534492

Martin TG, Langer SJ, Crocini C, Chung E, Leinwand LA. Activation of FoxO1 prevents and reverses cardiac hypertrophy from diverse stimuli. Journal of molecular and cellular cardiology. 2025. PMID: 40553761

Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO open. 2025. PMID: 40532364

Yang H, Song H, Yip E, Gilpatrick T, Chang K, Allegakoen P, Lu KL, Hui K, Pham JH, Kasap C, Kumar V, Gayle J, Stohr BA, Cornelia Ding CK, Wiita AP, Meng MV, Chou J, Porten SP, Huang FW. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature communications. 2025. PMID: 40527915

Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, Richardson G, Yan D, Lee MA, Lee KW, Pan H, Hager S, Li X, Wei S, Hou X, Underhill C, Millward M, Nordman I, Zhang J, Shan J, Han G, Grewal J, Gadgeel SM, Sanborn RE, Huh SJ, Hu X, Zhang Y, Xiang Z, Luo L, Xie X, Shi Z, Wang Y, Zhang L, Wang F, Xu RH. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal transduction and targeted therapy. 2025. PMID: 40523897

Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO precision oncology. 2025. PMID: 40526879

H. Geng, M. Randall, A. Ballapuram, L. Chen, C. Yung, M. Lu, C. Lowell, J. L. Rubenstein. THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:

D. A. Solomon, H. Geng, M. Randall, R. Sobel, J. Cleveland, A. Ballapuram, L. Chen, M. Lu, S. Cha, C. Lowell, W. P. Devine, J. L. Rubenstein. THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:

Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Pikman Y, Cheng ML, Logan AC, Stieglitz E, Smith CC. Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia. bioRxiv : the preprint server for biology. 2025. PMID: 40661530

Najjar YG, Orloff M, Mitchell TC, Bowles TL, Betof Warner A, Bollin K, Chandra S, Cohen JV, Eroglu Z, Funchain P, Gaughan E, Glitza Oliva I, Hsu S, Hu-Lieskovan S, Kennedy LB, Truong TG, McKean M, Mehnert J, Moon H, Tsai KK, Wilson M, Tran T, Buchbinder EI, Fecher LA, Guild S, Patel SP. Proceedings of the seventh annual Women in Melanoma Conference. Therapeutic advances in medical oncology. 2025. PMID: 40535733

Alexis LeVee, Saya Jacob, Samantha Fisch, Carolyne Face, Madhuri Chengappa, Saliha Chaudhry, Nikita Baclig, Andrew Soliman, Nora Ruel, Megan Wong, Karen Tsai, Irene Kang, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Melissa Lechner, Dame Idossa, Anne Blaes, Kelly McCann, Hope S. Rugo, Joanne Mortimer. Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy JA, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O'Regan R, Santarsiero L, Akdere M, Ye F, Scotchmer A, Graff SL. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis. ESMO open. 2025. PMID: 40516131

Nikita Baclig, Andrew Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyn Face, Madhuri Chengappa, Saliha Chaudhry, Dame Idossa, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Anne Blaes, Hope S. Rugo, Melissa Lechner, Kelly E. McCann. Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Madhuri Chengappa, Thejaswi K Poonacha, Nikitha Vobugari, Go Nishikawa, Saya Jacob, Samantha Fisch, Carolyn Face, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Kelly McCann, Hope S. Rugo, Dame Idossa, Anne Blaes. Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study. Clinical Cancer Research. 2025. PMID: